Table 4.
The targeted liposomal systems for breast cancer which have progressed to clinical trials.
| Name | Identifier | Target | Composition | Size (nm) | Last updated | Clinical phase | Status | Reference |
|---|---|---|---|---|---|---|---|---|
| MM-310 | NCT03076372 | EphA2, TNBC | ESM, CHOL, DSPE-mPEG (2000) | ∼100 | 2018 | I | Unknown* | [122] |
| MM-302 | NCT01304797, NCT02213744, NCT02735798 | HER2 | PC, CHOL, PEG, DSPE-PEG | 75–110 | 2017 | I, II, III | Unknown*, Terminated, Withdrawn |
[302,[381], [382], [383], [384]] |
| ONT-10 |
NCT01556789, NCT02270372, NCT01978964 |
MUC1, PET Lipid A | CHOL, DMPG, DPPC | 2018 | I, Ib, III | Completed, Completed, Completed |
[314,385,386] | |
| AS1411 | NCT01034410, NCT00881244, NCT00740441,NCT00512083 | Nucleolin | HSPC, CHOL, DSPE-mPEG (2000) | ∼200 | 2009, 2011 | I, II Not BC specifically but solid tumors |
Completed, Unknown*, Completed, Terminated |
[139] |
| LiPlaCis® | NCT01861496 | sPLA2-trigger | POPC, POPG, CHOL, DSPE-PEG (2000) | ∼130 | 2021 | I, II Issues with formulation |
Completed | [214,356,387,388] |
Eph: erythropoietin-producing hepatocellular receptor A2; CHOL: cholesterol; DMPG: dimyristoyl phosphatidylglycerol; DPPC: dipalmitoylphosphatidylcholine; DSPE: 1,2-distearoyl-sn-glycero-3-phosphorylethanolamine; ESM: sphingomyelin from egg; HER2: human epidermal receptor 2; HSPC: hydrogenated soybean phosphatidylcholine; MUC1: mucin 1; PC: phosphatidylcholine; PEG; polyethylene glycol; POPC: 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine; POPG: 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-(1′-rac-glycerol) sodium salt; sPLA2: secretory phospholipase A2; TNBC: triple negative breast cancer. * Study has passed its completion date and status has not been updated in over two years.